Predicting Alzheimer's Onset with Blood Tests: A New Frontier

Recent research from Washington University School of Medicine has introduced a blood test capable of predicting the onset of Alzheimer's disease symptoms within a margin of three to four years. This study, published in *Nature Medicine*, utilized levels of a protein called p-tau217 found in blood samples from over 600 cognitively healthy adults aged 62 to 78. The findings suggest that the accumulation of p-tau217 can serve as a biological clock for estimating when individuals may begin to experience symptoms of Alzheimer's.

Fierce BiotechNewsweekBlood test “clocks” predict when Alzheimer’s symptoms will start – WashU MedicineGizmodoScientific American

The researchers analyzed blood samples collected over a decade from participants in two major Alzheimer’s research initiatives: the WashU Knight Alzheimer Disease Research Center and the Alzheimer’s Disease Neuroimaging Initiative. They found that individuals who tested positive for elevated p-tau217 levels at age 60 typically developed symptoms approximately 20 years later, while those who tested positive at age 80 experienced symptoms within about 11 years. This indicates that older individuals may show symptoms sooner, even with lower levels of the disease markers.

NewsweekFierce BiotechBlood test “clocks” predict when Alzheimer’s symptoms will start – WashU MedicineGizmodoScientific American

The predictive model developed in this study could significantly enhance the efficiency of clinical trials for Alzheimer’s treatments. By identifying individuals likely to develop symptoms within a trial's timeframe, researchers can better select participants, thereby accelerating the development of preventive therapies. Suzanne Schindler, the study's senior author, emphasized that these blood tests are more accessible and cost-effective compared to traditional diagnostic methods like PET scans or spinal taps.

Blood test “clocks” predict when Alzheimer’s symptoms will start – WashU Medicine

Schindler noted, “Our work shows the feasibility of using blood tests... for predicting the onset of Alzheimer’s symptoms.” She highlighted the potential for these models to guide treatment plans for patients and their doctors. However, experts caution that these tests are not yet recommended for asymptomatic individuals outside of clinical research settings. Corey Bolton, a clinical neuropsychologist, stated, “While the results here are encouraging, they are not yet at the level of having significant clinical benefit for individual patients.”

Scientific American

Despite the promising results, some experts express caution regarding the accuracy of the tests. Zaldy Tan, a memory and aging specialist, pointed out that the three- to four-year error margin is significant, particularly for individuals making life-altering decisions based on the results. Additionally, other medical conditions can influence p-tau217 levels, potentially leading to false positives or negatives.

Scientific American

While the study presents a significant advancement, it also raises questions about its applicability across diverse populations. Experts like Nathaniel Chin have called for replication of the findings in broader demographic groups to ensure the model's robustness.

Scientific American

The research team is optimistic about refining the predictive models further, potentially incorporating additional blood biomarkers and cognitive measures to enhance accuracy. As the field of Alzheimer’s diagnostics evolves, these blood tests could eventually play a crucial role in early intervention strategies for those at risk of developing the disease.

Scientific American

In summary, while the study marks a significant step forward in Alzheimer’s research, further validation and refinement are necessary before these tests can be widely implemented in clinical practice.

Gizmodo